The aim of this study is to determine the efficacy of Sancuso® (granisetron transdermal
system) 3.1 mg/24 hours in improving symptoms of nausea and vomiting in patients with
gastroparesis. This will be a prospective open-label study using Sancuso® to treat symptoms
of nausea and/or vomiting in patients diagnosed with gastroparesis. Symptomatic patients with
diabetic or idiopathic gastroparesis with nausea and/or vomiting will be enrolled. The
Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) will be used to capture the
severity of symptoms, including nausea and vomiting, at baseline for one week. Patients will
then be treated with Sancuso®. Patients will continue to fill out the GCSI-DD on a daily
basis while undergoing treatment with Sancuso® for two weeks. To determine if Sancuso®
treatment helps improve symptoms of nausea and vomiting, the symptoms at baseline will be
compared to symptoms after the first week and the second week of treatment. Thirty patients
diagnosed with gastroparesis (approximately 15 with diabetic and 15 with idiopathic
gastroparesis) will be treated on an open label basis with Sancuso®. The goal of this study
is to demonstrate the efficacy of Sancuso® in treating nausea and/or vomiting in
gastroparesis patients. Safety information will also be collected regarding any adverse
effects. If the results are encouraging, as we expect them to be based on personal
experience, a larger double blind study would be appropriate.